Genmab — Marts 2014
-
har ikke hørt noget om impact fra ibrutinib i cll fra GSK
-
han snakker igen kombinationer
-
taler om kombo data med ibrutinib - som er "incredibly strong"
-
så få da gang i det phase III !
-
hans begejstring for hexa var da ikke til at misforstå!
-
dara milestone ca 75 mio usd pa
-
over de næste 4 år
-
de deler bare milestones ud fordelt ligeligt over 8 år (600 mio. $) så det kan faktisk blive mere i 2014 end de 250 mio. kr. !
-
Det de har indregnet er bare et gns. estimat
-
Deutsche med nu
-
spørger om dara og om investeringstanker på emissionspenge
-
- spm late cycle review mellem FDA og GSK...
-
dara recruitment - going very well, massive interest doctors and patients
-
en hurtig rekruttering i pivotalstudiet med Dara
-
stor interesse for klinikker om at være med
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind